← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Arteriocyte, Inc.
Cleveland, OH
$14,079,209
Total funding
14
Grants
Funding over time
peak $6.4M · FY2005–20$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
DOD$8,036,283 · 6
NIH$6,042,926 · 8
By mechanism
—$8,036,283 · 6
R44$3,288,425 · 2
R42$1,410,063 · 1
R43$1,033,793 · 4
R41$310,645 · 1
Investigators at Arteriocyte, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
AUTOLOGOUS BONE MARROW DERIVED MONONUCLEAR CELL THERAPY FOR COMPARTMENT SYNDROME YEAR 3 AND 4.$2,444,439
· FY2011 · Department of Defense
AUTOLOGOUS BONE MARROW DERIVED MONNUCLEAR CELL THERAPY$1,881,170
· FY2009 · Department of Defense
ARTERIOCYTE'S MAGELLAN AUTOLOGOUS PLATELET RICH PLASMA AND BONE MARROW DERIVED STEM CELL BASED THERAPIES FOR BURN WOUNDS$1,746,063
· FY2011 · Department of Defense
Therapeutic Potential of Ex vivo expanded Human Cord Blood derived CD133+ cells i$1,609,381
R44 · FY2010 · HL
ARTERIOCYTE MAGELLAN PLATELET RICH PLASMA INFECTION PREVENTION STRATEGIES$1,395,834
· FY2011 · Department of Defense
Marrow-Derived Stem Cells for Coronary Artery Ischemia$1,229,607
R42 · FY2006 · HL
Therapeutic Potential of Ex vivo expanded Human Cord Blood derived CD133+ cells i$586,833
R44 · FY2011 · HL
Biomaterial augmented microfracture repair of full-thickness chondral defects04$508,141
R44 · FY2016 · AR
NOVEL DEVICE FOR DIAGNOSIS AND MONITORING OF COMPARTMENT SYNDROME VIA DIRECT TISSUE OXYGEN MEASUREMENTS$402,311
· FY2017 · Department of the Army
CAN CD 133 CELLS PREVENT HYPOXIA DRIVEN RETINAL NEOVASCULARISATION IN A RODENT MO$310,645
R41 · FY2007 · EY
A Novel Expansion of Primary Leukemia Stem Cells$304,943
R43 · FY2010 · CA
Biomaterial augmented microfracture repair of full-thickness chondral defects04$302,276
R44 · FY2017 · AR
Hematopoietic Reconstitution Using Ex Vivo Expanded Cord Blood CD34+ Cells$283,861
R43 · FY2012 · HL
Therapeutic Potential of Ex vivo expanded Human Cord Blood derived CD133+ cells i$281,794
R44 · FY2008 · HL
Scalable manufacturing of human platelet lysate for next generation cell-based technologies$224,994
R43 · FY2019 · GM
RAPID, HIGH VOLUME PRODUCTION OF RETICULOCYTES FOR P. VIVAX MALARIA RESEARCH$219,995
R43 · FY2011 · AI
NEW AWARD - ALLOPLEX: A MULTIFUNCTIONAL, BIOACTIVE DRESSING FOR BURN WOUND CARE IN THE PREHOSPITAL ENVIRONMENT, SIGNED 4/14/2020, EFFECTIVE 5/1/2020, DISTRIBUTED 4/15/2020, FAADC 4/15/2020$166,465
· FY2020 · Defense Health Agency
Marrow-Derived Stem Cells for Coronary Artery Ischemia$142,954
R42 · FY2005 · HL
Marrow-Derived Stem Cells for Coronary Artery Ischemia$37,502
R42 · FY2007 · HL